2.04
1.92%
-0.04
After Hours:
2.04
Pulmatrix Inc stock is currently priced at $2.04, with a 24-hour trading volume of 6,762.
It has seen a -1.92% decreased in the last 24 hours and a +20.66% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.06 pivot point. If it approaches the $2.02 support level, significant changes may occur.
Previous Close:
$2.08
Open:
$2.07
24h Volume:
6,762
Market Cap:
$7.45M
Revenue:
$7.30M
Net Income/Loss:
$-14.12M
P/E Ratio:
-0.4206
EPS:
-4.85
Net Cash Flow:
$-16.66M
1W Performance:
+2.53%
1M Performance:
+20.66%
6M Performance:
+9.10%
1Y Performance:
-25.55%
Pulmatrix Inc Stock (PULM) Company Profile
Name
Pulmatrix Inc
Sector
Industry
Phone
781 357 2333
Address
99 Hayden Avenue, Suite 390, Lexington, MA
Pulmatrix Inc Stock (PULM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-09-18 | Initiated | H.C. Wainwright | Buy |
Pulmatrix Inc Stock (PULM) Financials Data
Pulmatrix Inc (PULM) Revenue 2024
PULM reported a revenue (TTM) of $7.30 million for the quarter ending December 31, 2023, a +20.21% rise year-over-year.
Pulmatrix Inc (PULM) Net Income 2024
PULM net income (TTM) was -$14.12 million for the quarter ending December 31, 2023, a +25.03% increase year-over-year.
Pulmatrix Inc (PULM) Cash Flow 2024
PULM recorded a free cash flow (TTM) of -$16.66 million for the quarter ending December 31, 2023, a +14.30% increase year-over-year.
Pulmatrix Inc (PULM) Earnings per Share 2024
PULM earnings per share (TTM) was -$3.86 for the quarter ending December 31, 2023, a +29.30% growth year-over-year.
About Pulmatrix Inc
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Cap:
|
Volume (24h):